Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 3, 2011, Pages 531-539

  Sen, P ^a   Komissarov, A A ^a   Florova, G ^a   Idell, S ^a   Pendurthi, U R ^a   Vijaya Mohan Rao, L ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Factor VIIa; Plasminogen activator inhibitor 1; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; VITRONECTIN;

ARTICLE; CELL SURFACE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

CELL MEMBRANE; CELLS, CULTURED; FACTOR VIIA; HEMOSTASIS; HUMANS; KINETICS; MULTIPROTEIN COMPLEXES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; RECOMBINANT PROTEINS; THROMBOPLASTIN; VITRONECTIN;

EID: 79952048167     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04167.x     Document Type: Article

References (48)

1. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-64.
2. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31: S213-20.
3. Mutsaers SE, Prele CM, Brody AR, Idell S. Pathogenesis of pleural fibrosis. Respirology 2004; 9: 428-40.
4. Broze GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
5. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-21.
6. Rao LVM, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-9.
7. Gils A, Declerck PJ. Plasminogen activator inhibitor-1. Curr Med Chem 2004; 11: 2323-34.
8. Ehrlich HJ, Gebbink RK, Keiher J, Linders M, Preissner KT, Pannekoek H. Alternation of serpin specificity by a protein cofactor vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
9. Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-61.
10. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-70.
11. Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11: 183-93.
12. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
13. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol 1996; 16: 1277-84.
14. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996; 75: 451-61.
15. Idell S, Girard W, Koenig KB, Mclarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991; 144: 187-94.
16. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, Mclarty J, Fair DS. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84: 695-705.
17. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44.
18. Welty-wolf KE, Carraway MS, Ortel TL, Piantadosi CA. Coagulation and inflammation in acute lung injury. Thromb Haemost 2002; 88: 17-25.
19. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-4.
20. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-83.
21. Komissarov AA, Declerck PJ, Shore JD. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 2002; 277: 43858-65.
22. Rao LVM, Williams T, Rapaport SI. Studies of the activation of factor VII bound to tissue factor. Blood 1996; 87: 3738-48.
23. Mandal SK, Pendurthi UR, Rao LV. Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling. Blood 2007; 110: 161-70.
24. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
25. Pendurthi UR, Williams JT, Rao LVM. Acidic and basic fibroblast growth factors suppress transcriptional activation of tissue factor and other inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 940-6.
26. Rao LVM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-7.
27. Ardissino D, Merlini PA, Arlens R, Coppola R, Bramucci E, Lucreziotti S, Repetto A, Fetiveau R, Mannucci PM. Tissue factor in human coronary atherosclerotic plaques. Clin Chim Acta 2000; 291: 235-40.
28. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
29. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6: S7-13.
30. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
31. Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121-2215.
32. de Fouw NJ, van Hinsbergh VW, de Jong YF, Haverkate F, Bertina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987; 57: 176-82.
33. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D. Kinetics of inactivation of a-thrombin by plasminogen activator inhibitor-1. J Biol Chem 1993; 268: 12367-72.
34. Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 1991; 115: 1773-81.
35. Ehrlich HJ, Keijer J, Preissner KT, Gebbink RK, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30: 1021-8.
36. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 767-70.
37. Olsen OH, Persson E. Cofactor-induced and mutational activity enhancement of coagulation factor VIIa. Cell Mol Life Sci 2008; 65: 953-63.
38. Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009; 14: 1337-61.
39. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-40.
40. Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994; 33: 12686-94.
41. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 4378-86.
42. Salemink I, Franssen J, Willems GM, Hemker HC, Lindhout T. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition. J Biol Chem 1999; 274: 28225-32.
43. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ. Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 1997; 107: 313-20.
44. Stoop AA, Lupu F, Pannekock H. Colocalization of Thrombin, PAI-1, and vitronectin in the artherosclerotic vessel wall. Arterioscler Thromb Vasc Biol 2000; 20: 1143-9.
45. Wilcox JN, Noguchi S, Casanova JR, Rasmussen MR. Extrahepatic synthesis of FVII in human atheroma and smooth muscle cells in vitro. Ann N Y Acad Sci 2004; 947: 433-8.
46. Idell S, Gonzalez K, Bradford H, MacArthur CK, Fein AM, Maunder RJ, Garcia JGN, Griffith DE, Weiland J, Martin TR, Mclarty J, Fair DS, Walsh PN, Colman RW. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome - contribution of tissue factor associated with factor VII. Am Rev Respir Dis 1987; 136: 1466-74.
47. Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells. Eur Respir J 2000; 15: 1069-78.
48. Laake K, Osterud B. Activation of purified plasma factor VII by human plasmin, plasma kallikrein, and activated components of the human intrinsic blood coagulation system. Thromb Res 1974; 5: 759-72.